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Abstract: Given evidence of increasing prevalence in developed and developing countries, as a result of obesity trends 
and sedentary lifestyles, the metabolic syndrome represents an increasing burden on healthcare systems. Management 
guidelines for dyslipidaemia have primarily focused on LDL-C reduction; however, this approach fails to sufficiently 
address other lipid abnormalities associated with the metabolic syndrome. Atherogenic dyslipidaemia (characterized by 
elevated triglycerides and low HDL-C) is strongly associated with insulin-resistant states, such as type 2 diabetes and the 
metabolic syndrome, and is also a common finding among patients receiving treatment for dyslipidaemia. Intervening 
against atherogenic dyslipidaemia may address a substantial modifiable fraction of residual cardiovascular risk that 
remains after treatment with a statin. Recent findings from the Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study support this view. Fenofibrate treatment was shown to be especially effective in treating marked 
atherogenic dyslipidaemia, with a significant 27% relative risk reduction for cardiovascular events (P=0.0005, vs. 11%, 
P=0.035 for all patients) relative to placebo. These data, together with the earlier demonstration of significant 
microvascular benefits associated with this treatment, suggest a role for fenofibrate, in addition to statin therapy and 
lifestyle intervention, for reducing global vascular risk in type 2 diabetes patients and for impacting atherogenic 
dyslipidaemia associated with the metabolic syndrome. 
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INTRODUCTION 
  While mortality rates from cardiovascular disease have 
declined in recent decades, global trends including increa-
sing prevalence of type 2 diabetes and the continuing ten-
dency towards the adoption of sedentary lifestyles and high-
energy diets in developing countries, threaten to slow or 
even reverse this progress. There is no doubt that aggressive 
multifactorial intervention to address cardiometabolic risk 
factors can have a major impact on the risk of adverse 
cardiovascular outcomes, and continuing research will refine 
our ideas on how, when and to whom to apply such 
interventions. This is especially relevant for individuals with 
type 2 diabetes and/or the metabolic syndrome. Recent 
analyses from the large Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) study have shed new light on 
the management of cardiovascular risk in this population. 
This review examines these new data in the light of the 
management of cardiovascular risk in patients with type 2 
diabetes and features of the metabolic syndrome. 
CURRENT FOCUS OF LIPID-MODIFYING 
THERAPY 
  Current guidelines for the management of the lipid 
profile continue to strongly focus on the control of choles-
terol associated with the major circulating atherogenic 
lipoprotein (i.e. apolipoprotein B100 [ApoB]-containing lipo- 
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proteins, mostly low-density lipoproteins [LDL] and/or of 
total cholesterol). The US National Cholesterol Education 
Program/Adult Treatment Panel III (NCEP/ATP III) recom-
mends that “LDL-cholesterol (LDL-C) be the primary target 
of therapy [1].” Goals for LDL-C are provided for different 
risk categories: <100 mg/dL (2.6 mmol/L) for patients with 
coronary heart disease (CHD) or CHD equivalents (such as 
type 2 diabetes), <130 mg/dL (3.4 mmol/L) for patients with 
two or more standard cardiovascular risk factors, and <160 
mg/dL (4.1 mmol/L) for patients with no more than one 
cardiovascular risk factor. The guidelines from the European 
Society of Cardiology (ESC) recommend management of 
cholesterol within the broader framework of global cardio-
vascular risk, including overweight, obesity, hypertension 
and smoking, with cholesterol goals <5 mmol/L (about 190 
mg/dL) for total cholesterol and <3 mmol/L (about 115 
mg/dL) for LDL-C in low-risk patients [2]. Again, there are 
more stringent goals for patients in higher cardiovascular 
risk categories of <4-4.5 mmol/L (about 155–175 mg/dL) 
and 2-2.5 mmol/L (about 80-100 mg/dL) where feasible.  
  Non-HDL-C (the combined cholesterol load from very 
low-density lipoproteins [VLDL], intermediate-density 
lipoproteins [IDL], LDL and other remnants) was proposed 
as secondary target for therapy beyond LDL-C in the 
NCEP/ATPIII guidelines for people with triglycerides 2.3 
mmol/L (200 mg/dL) [1]. One rationale was that as 
triglycerides rise, LDL-C estimation using Friedewald’s 
formula tends to underestimate the true levels of LDL-C. 
Another is that non-HDL-C provides additional information 
on the level of all atherogenic lipoproteins, including those 
of intermediate size generated during ongoing triglycerides 
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and correlates closely with ApoB levels. In addition, these 
guidelines provide some support for intervention to correct 
atherogenic dyslipidaemia (low HDL-C and/or high trigly-
cerides), with primary emphasis on lifestyle intervention. 
HDL-C <1.03 mmol/L (40 mg/dL) and <1.29 (50 mg/dL) is 
recognized as ‘too low’ for men and women, respectively, 
although no specific goal value for raising this parameter 
was identified as target for therapy. Similarly, European 
guidelines for cardiovascular risk reduction do not propose 
goal values for HDL-C or triglycerides [2].  
  In practice, control of LDL-C usually means intervention 
with a statin (occasionally combined with ezetimibe) where 
lifestyle interventions (diet and exercise) are insufficiently 
effective. There is no doubt that this strategy has delivered 
substantial reductions in the risk for cardiovascular events in 
at-risk populations, both in primary and secondary cardio-
vascular prevention. Large prospective studies have demons-
trated relative reductions in risk of cardiovascular events of 
20–50% depending on the baseline level of risk [3].  
ATHEROGENIC DYSLIPIDAEMIA, METABOLIC 
SYNDROME AND CARDIOVASCULAR RISK 
Diagnosing the Metabolic Syndrome 
  The metabolic syndrome represents both an important 
source as well as an estimate of global cardiovascular risk in 
addition to hypercholesterolaemia and other standard risk 
factors, such as smoking and familial cardiovascular history. 
The condition describes a clustering of cardiovascular risk 
factors in patients with insulin-resistant states, including 
obesity, hypertension, coronary heart disease and/or type 2 
diabetes. The most commonly-used diagnostic criteria for the 
metabolic syndrome have been proposed jointly by various 
scientific bodies, such as the NCEP/ATPIII, the American 
Heart Association (AHA/NHLBI) [1, 4], and the Inter-
national Diabetes Federation (IDF) [5]. Each presents a set 
of five individual criteria based on levels of (or specific 
treatment for) waist circumference, HDL-C, triglycerides, 
fasting glucose and blood pressure, and requires the presence 
of three or more of these five easily-obtained anthropometric 
or biochemical cardiovascular risk factors to support a 
diagnosis of the metabolic syndrome.  
  The main difference between these definitions in terms of 
practical diagnosis is that meeting any three criteria is 
sufficient to support the diagnosis of metabolic syndrome 
according to the NCEP/ATPIII or the AHA/NHLBI, while 
the IDF require abdominal obesity (high waist circum-
ference) as sine qua non criterion plus two or more other 
criteria. In addition, the IDF provide lower and ethnic-
specific cut-offs for waist circumference relative to the 
NCEP/ATPIII. Other differences include lower cut-off 
values for fasting glucose (although a threshold of 100 
mg/dL was subsequently endorsed by other definitions), and 
the inclusion of treatment for any specific abnormality in 
addition to absolute levels of metabolic parameters, in the 
IDF criteria. 
High Prevalence of Metabolic Syndrome in Type 2 
Diabetes Patients 
  The prevalence of the metabolic syndrome in non-
diabetic patients in western countries is in the region of 25–
35%, depending on the diagnostic criteria used [6-8]. 
However, prevalence appears to be considerably higher in 
patients with type 2 diabetes. For example, about 80% of 
type 2 diabetes patients from Finland or Sweden in the 
Botnia cohort had metabolic syndrome [6]. Additionally, 
high prevalence rates of NCEP/ATPIII metabolic syndrome 
have been demonstrated among the populations of major 
clinical trials in exclusively type 2 diabetes populations, such 
as the United Kingdom Prospective Diabetes Study 
(UKPDS) (61%) [9], and the FIELD study (>80%), the latter 
population being largely without cardiovascular disease at 
baseline [10].  
  These observations are consistent with the underlying 
pathology of type 2 diabetes. Patients with type 2 diabetes 
meet the diagnostic criterion relating to hyperglycaemia, by 
definition. In addition, both hypertension and an atherogenic 
dyslipidaemia phenotype (characterized by low HDL-C, 
elevated triglycerides and an increase in small, dense LDL), 
are associated strongly with insulin resistance and com-
pensatory hyperinsulinaemia. These abnormalities are the 
hallmark of many insulin-resistant states, such as the meta-
bolic syndrome and the common form of type 2 diabetes [11, 
12]. A survey conducted in >8000 patients receiving treat-
ment for dyslipidaemia, (mostly with a statin) in 11 Euro-
pean countries confirmed a higher prevalence of low HDL-C 
and/or hypertriglyceridaemia in patients with type 2 diabetes, 
relative to patients without diabetes (Table 1) [13, 14].  
Table 1.  Prevalence of Features of Atherogenic Dyslipidaemia 
in Patients With or Without Type 2 Diabetes (T2D) in 
a Survey Conducted in 11 European Countries 
 Men  Women 




No T2D (%) 
Low HDL-C  38  29  50  30 
High TG  55  43  54  35 
Low HDL-C 
and high TG 
27 18 34  17 
 
  National Cholesterol Education Program/Adult Treat-
ment Panel III cut-off values used to determine low or high 
lipid parameters. Type 2 diabetes was present in 3866 
patients and absent in 4436 patients. HDL-C: high-density 
lipoprotein cholesterol; TG:  triglycerides. Data from 
Bruckert et al. [13,14]. 
Metabolic Syndrome and Adverse Cardiovascular 
Outcomes 
  A number of studies have associated the metabolic 
syndrome significantly and independently with an increased 
risk for type 2 diabetes or cardiovascular disease [15-18]. 
Importantly, the presence of the metabolic syndrome accen-
tuates cardiovascular risk associated with type 2 diabetes, 
seemingly above the summative risk afforded by its discrete 
components. An analysis from the Botnia cohort illustrates 
this point. Within a cohort of 4483 subjects aged 35–70 
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using alternative criteria from the World Health Organi-
sation) increased the risk of pre-existing coronary heart 
disease in patients with normal glucose homeostasis or with 
pre-diabetic states (impaired fasting glucose and/or impaired 
glucose tolerance), or a clinical diagnosis of type 2 diabetes 
(Fig.  1). The presence of the metabolic syndrome also 
increased the risk of stroke by about 2–fold in the overall 
population (P<0.001), although increases in relative risk 
associated with the metabolic syndrome did not achieve 
statistical significance after stratification of the population 












Fig. (1). Impact of the metabolic syndrome on the risk of 
cardiovascular disease according to glycaemic status in the Botnia 
Study. 
Coronary heart disease (CHD) was defined as use of nitroglycerine 
or prior myocardial infarction (MI). Relative risks were adjusted for 
age and gender. IFG: impaired fasting glucose; IGT: impaired 
glucose tolerance. Drawn from data presented by Isomaa et al. [6].  
 
  Longitudinal data confirm the strong association between 
the metabolic syndrome and adverse cardiovascular out-
comes in patients with type 2 diabetes. A post-hoc analysis 
from the UKPDS studied the incidence of micro- and 
macrovascular complications with respect to baseline 
metabolic syndrome in a subset of 4542 newly-diagnosed 
type 2 diabetes patients over an average follow-up duration 
of 10 years [9]. The risk of macrovascular complications was 
markedly and significantly higher in patients with metabolic 
syndrome, with increases in the risk of cardiovascular 
disease or myocardial infarction of about 30% and an 
increase in the risk of stroke of about 70% in patients fulfil-
ling NCCEP/ATPIII criteria. Although the risk of micro-
vascular complications was not captured by metabolic 
syndrome identification in the UKPDS, other studies, for 
example the Metascreen study [19], have reported an increa-
sed risk of macrovascular and microvascular complications 
in type 2 diabetic patients with metabolic syndrome defined 
according to AHA/NHLBI or IDF criteria.  
  In the FIELD study, features of atherogenic dyslipi-
daemia (hypertriglyceridaemia and/or low HDL-C) were 
more strongly associated with increased cardiovascular event 
rates than the two other, non-glycaemic diagnostic criteria 
for the metabolic syndrome (Fig. 2). Incident cardiovascular 
disease rate increased in line with the number of non-glycae-
mic metabolic syndrome criteria in addition to type 2 dia-
betes in this study. Relatively little interaction was observed 
between high blood pressure and the metabolic syndrome, as 
cardiovascular event rates were only about 10% higher in 
hypertensive patients with vs. without the metabolic syn-
drome. Similarly, the presence of the metabolic syndrome 
increased cardiovascular event rates by about 30% relative to 
patients without the metabolic syndrome in patients with 
abdominal obesity. However, the greatest impact of the 
metabolic syndrome on cardiovascular prognosis was obser-
ved in patients with marked hypertriglyceridaemia (2.3 
mmol/L or 200 mg/dL) or low HDL-C, where the presence 
of the metabolic syndrome increased cardiovascular event 
rates by about 2.8-fold and by about 2-fold, respectively. 
  Whether the metabolic syndrome is itself a driver of 
excess cardiovascular risk, or whether the individual risk 
factors included in its diagnostic criteria account for all of 
the excess adverse cardiovascular outcomes in these patients 
is contentious [20, 21]. It is important to note here that the 
diagnostic criteria of the metabolic syndrome represent only 
a few of the metabolic abnormalities associated with it. A 
range of other cardiovascular risk factors also tends to 
cluster in patients with the metabolic syndrome, such as a 
prothrombotic state, oxidative stress, endothelial dysfunc-
tion, low-grade systemic inflammation and/or albuminuria. 
These are all likely to contribute to (or reflect) to a greater or 
lesser extent the development (or the burden) of premature 
atherosclerotic cardiovascular disease [22]. 
REDUCING CARDIOVASCULAR RISK IN TYPE 2 
DIABETES PATIENTS WITH METABOLIC 
SYNDROME 
Pathophysiologic Considerations 
  The data summarized above suggest that the presence of 
the metabolic syndrome is likely to be useful in identifying 
type 2 diabetes patients at markedly increased cardiovascular 
risk who would benefit from intensive intervention [23]. 
Identifying a metabolic syndrome phenotype may be used 
either as a dichotomic state (presence or absence), whereas 
score ranking within metabolic syndrome patients may even 
represent stepwise rise in cardiovascular risk (from 3/5 to 
5/5). The data from the FIELD study, in particular, highlight 
atherogenic dyslipidaemia as an important source of modi-
fiable cardiovascular risk in this population. Thus, treatments 
which target atherogenic dyslipidaemia and other risk factors 
associated with type 2 diabetes and the metabolic syndrome 
represent a rational approach to the management of this 
population. Peroxisome proliferator activator receptor- 
(PPAR), a nuclear receptor with important transcriptional 
regulator activity on lipid metabolism, energy balance and 
inflammation, has emerged as a logical target for therapeutic 
intervention in metabolic syndrome and type 2 diabetes [24, 
25]. As pharmacological agents, fibric acid derivatives exert 
their therapeutic action by activating PPAR. Fenofibrate, a 
member of this therapeutic class, is a PPAR ligand which 
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to reduce triglycerides by up to 50%, dependent on baseline 
levels [26-28]. In addition, fenofibrate induces a shift in the 
subclass distribution of LDL from small, dense LDL to 
larger particles, usually associated with lesser atherogenic 
profiles [29, 30].  
 Fig.  (3) shows the effects of fenofibrate, simvastatin and 
both agents in combination, on these parameters in a 12-
week, randomized trial in patients with type 2 diabetes and 
mixed dyslipidaemia [28, 30]. Fenofibrate was more effec-
tive than simvastatin in increasing HDL-C and decreasing 
triglycerides, and simvastatin was more effective in reducing 
LDL-C, as would be expected from their mode of action. 
However, fenofibrate, but not simvastatin, significantly 
decreased the proportion of LDL in the small, dense (pattern 
B) subclass, and increased the proportion of larger, more 
buoyant LDL. Overall, the combination treatment resulted in 
the least atherogenic lipid profile. These and other studies 
have also shown that treatment with fenofibrate reduced a 
series of markers of chronic low-grade systemic inflam-
mation, which have been implicated in the pathogenesis of 
atherosclerosis or thought of as reflecting its burden [25, 26, 
31, 32]. Thus, fenofibrate modulates both key factors and 
markers of cardiovascular risk associated with the metabolic 
syndrome that are not adequately addressed by statins. 
EXPERIENCE FROM THE FIELD STUDY 
Overview of FIELD 
  In the FIELD study, 9795 patients with type 2 diabetes 
were randomized to receive treatment with fenofibrate or 
placebo for an average of 5 years [33, 34]. The study 
population as a whole was at relatively low cardiovascular 
risk; patients with an indication for treatment with a statin at 
baseline were ineligible for the trial, and only 22% had pre-
existing cardiovascular disease. Although a reduction of 11% 
vs. placebo in the primary composite endpoint (nonfatal 
myocardial infarction or coronary heart disease death) did 
not achieve statistical significance (hazard ratio [HR] 0.89 
[95% CI 0.75 to 0.15], P=0.16), randomization to fenofibrate 
was associated with significant reductions in the risk of 
nonfatal myocardial infarction (-24%; HR 0.76 [95% CI 0.62 
to 0.94], p=0.01), any cardiovascular disease event (-11%; 
HR 0.89 [95% CI 0.80 to 0.99], P=0.035), coronary 


















Fig. (2). Cardiovascular disease (CVD) event rates in patients with features of the metabolic syndrome in the FIELD study. 
Dotted lines represent CVD event rates in patients fulfilling the criteria for National Cholesterol Education Program/Adult Treatment Panel 
III metabolic syndrome. Individual criteria were as follows:  waist: waist circumference >102 cm for men or >88 cm for women;  BP 
>135/>85 mmHg;  HDL: HDL-C <1.03 mmol/L for men or <1.29 mmol/L for women;  TG: triglycerides >1.7 mmol/L;  TG: 
triglycerides >2.3 mmol/L. Drawn from data presented by Scott et al. [10].  116    Current Cardiology Reviews, 2010, Vol. 6, No. 2  Michel P. Hermans 
P=0.003) and any revascularization (-20%; HR 0·80 [95% CI 
0.70 to 0.92], p=0.001). A marked reduction in micro-
vascular complications was also observed in the fenofibrate 
group, including reductions relative to placebo in risk of 
retinopathy (especially in patients without prior retinopathy), 
lower-limb non-traumatic amputation, or progression of 
nephropathy markers [35, 36]. Fenofibrate was well tole-
rated, with an incidence of side-effects similar to placebo. In 
particular there was no excess of musculoskeletal serious 
adverse events with fenofibrate (15% in either group) and 
only four cases of rhabdomyolysis occurred (one in a patient 
on placebo and three in patients on fenofibrate, none of 
whom were receiving a statin). 
Patients With Features of the Metabolic Syndrome 
  The latest analysis from the FIELD study concerns the 
effects of fenofibrate in patients with cardiovascular risk 
factors featuring the metabolic syndrome [10]. As expected 
in a type 2 diabetes population, the proportions of patients 
who fulfilled diagnostic criteria for NCEP/ATPIII metabolic 
syndrome were high and similar in the placebo (84%) and 
fenofibrate groups (83%). More women (91%) than men 
(79%) had the metabolic syndrome at baseline. All patients 
met the diagnostic criterion relating to hyperglycaemia, as 
this was an exclusively type 2 diabetes population. More 
women than men were abdominally obese (83% and 59%, 
respectively) or had low HDL-C (67% and 55%, respec-
tively); similar proportions of women and men had hyper-
triglyceridaemia (55% and 50%, respectively) or high blood 
pressure (86% and 82%, respectively). 
  The effects of fenofibrate on the risk of incident 
cardiovascular events in patients stratified for the presence of 
various features of the metabolic syndrome are shown in Fig. 
(4). A risk reduction of 11% for fenofibrate vs. placebo in 
patients with the metabolic syndrome was similar in 
magnitude to the effect of fenofibrate in the overall popu-
lation, but marginally failed to reach statistical significance 
(P=0.052). With regard to individual metabolic syndrome 
criteria, significant adjusted risk reductions were observed in 
patients with raised blood pressure and low HDL-C (–12% 
and -14%, respectively). However, the largest risk reductions 
occurred in patients with coexisting marked hypertri-
glyceridaemia and low HDL-C, representing the most 
comorbid combination in atherogenic dyslipidaemia (-27%, 
P=0.005). The magnitude of this reduction was in line with 
the risk reduction observed in landmark statin trials perfor-
med in nondiabetic and diabetic cohorts.  
CONCLUSIONS 
  Atherogenic dyslipidaemia is commonly observed among 
patients under treatment for dyslipidaemia and is an impor-
tant effector of cardiovascular risk. Recent findings from the 
FIELD study indicate that not only are type 2 diabetes 
patients with atherogenic dyslipidaemia at greatest risk for 
cardiovascular events, but that fenofibrate was most effective 
















Fig. (3). Effects of fenofibrate on lipid parameters and LDL subclass profile in a randomized trial in patients with mixed hyperlipidaemia. 
aLDL3 and LDL4 cholesterol; 
bLDL1 and LDL2 cholesterol. †P<0.001; ‡P<0.0001 vs. baseline. HDL-C: high-density lipoprotein cholesterol; 
LDL-C: low-density lipoprotein cholesterol, TG: triglycerides. Drawn from data presented by Muhlestein et al. [28] and May et al. [30].  Antithrombotic Therapy in Cardiac Embolism  Current Cardiology Reviews, 2010, Vol. 6, No. 2    117 
demonstration of significant microvascular benefits asso-
ciated with this treatment suggest a role for fenofibrate, in 
addition to statin therapy and lifestyle intervention, for 
reducing this residual vascular risk in type 2 diabetes 
patients with atherogenic dyslipidaemia.  
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